Return to search results
Risedronate sodium
Risedronate Sodium is a generic bisphosphonate medication used to treat and prevent osteoporosis by strengthening bones. It comes as a 35 mg delayed-release oral tablet, manufactured by Sun Pharmaceutical Industries Inc. under ANDA203925. This product is discontinued. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Risedronate Sodium is a generic bisphosphonate medication used to treat and prevent osteoporosis by strengthening bones. It comes as a 35 mg delayed-release oral tablet, manufactured by Sun Pharmaceutical Industries Inc. under ANDA203925. This product is discontinued. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Risedronate sodium",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Risedronate sodium — ANDA 203925 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203925"
}
]
|
| identifier | ANDA203925 |
| issued | 2016-09-16 |
| keyword |
[
"drug-safety",
"fda",
"medications",
"pharmaceuticals",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Risedronate sodium |
